Loading the section…

AGIO: financial statements from SEC — TradeAlmanac

AGIO

Agios Pharmaceuticals, Inc.: financial statements

Company reports as filed with the U.S. Securities and Exchange Commission.

AnnualQuarterly

Income statement

Metric	31/03/2026	30/09/2025	30/06/2025	31/03/2025	30/09/2024	30/06/2024
Revenue	21M	13M	12M	9M	9M	9M
Cost of revenue	1M	2M	2M	1M	783,000	1M
Research and development	81M	87M	92M	73M	72M	77M
Selling, general and administrative	48M	41M	46M	42M	39M	36M
Operating expenses	131M	130M	140M	115M	112M	114M
Operating income	−110M	−117M	−127M	−107M	−103M	−106M
Pre-tax income	—	−103M	—	—	1.00B	—
Income tax	—	0	—	—	53M	—
Net income	−99M	−103M	−112M	−89M	948M	−96M
Earnings per share	−1.69	−1.78	−1.93	−1.55	16.65	−1.69
Earnings per share, diluted	−1.69	−1.78	−1.93	−1.55	16.22	−1.69
Weighted average shares	59M	58M	58M	57M	57M	57M
Weighted average shares, diluted	59M	58M	58M	57M	58M	57M

Balance sheet

Metric	31/03/2026	31/12/2025	30/09/2025	30/06/2025	31/03/2025	31/12/2024	30/09/2024	30/06/2024
Cash and equivalents	114M	89M	93M	81M	79M	76M	254M	85M
Inventory	35M	33M	32M

Cash flow

Metric	31/03/2026	31/03/2025
Operating cash flow	−119M	−111M
Share-based compensation	16M	11M
Capital expenditure	769,000	766,000
Investing cash flow	141M	113M
Financing cash flow	2M	2M

Amounts in USD unless stated otherwise. Data: US exchange trading and company filings with the regulator